Neuraxis, INC

Neuraxis, Inc. announced a stock dividend for its Series B Preferred Stock, payable in common stock on July 29, 2026.

Neuraxis stockholders approved the election of six directors and ratified amendments to the company's incentive and employee stock purchase plans.

Neuraxis, Inc. has filed to increase its at-the-market equity offering capacity to an aggregate of $11.5 million.

Neuraxis, Inc. announced preliminary unaudited financial results for the first quarter of 2026, highlighting revenue growth to $1.6 million.

Neuraxis, Inc. announced FDA 510(k) clearance for its PENFS technology for functional abdominal pain and functional dyspepsia, and increased its At The Market offering capacity to $6.27 million.

Neuraxis, Inc. disclosed preliminary unaudited financial results for the third quarter and nine months ended September 30, 2025, showing increased year-to-date sales but a quarterly operating loss.

Neuraxis, Inc. announced its first quarter 2026 financial results, showcasing a significant 79.5% year-over-year increase in net sales driven by expanded insurance coverage for its IB-Stim device.

NeurAxis, Inc. reported increased net sales for Q3 and the nine months ended September 30, 2025, but continues to face significant operating losses and a going concern warning from its auditors.

Neuraxis, Inc. reported increased net sales and a reduced net loss for Q2 2025, bolstered by a significant capital raise, despite ongoing operational losses and a 'going concern' warning.

NeurAxis, Inc. reports a revenue increase of 38.5% year-over-year for Q1 2025, but also a widening net loss due to increased expenses.

Neuraxis Inc. saw a revenue increase in Q3 2024, but continues to operate at a loss while addressing internal control weaknesses.

NeurAxis Inc. reported a decrease in revenue for the second quarter of 2024, alongside increased operating losses, as the company focuses on securing insurance coverage and managing its transition to a public entity.

Neuraxis, Inc. reported increased net sales for 2025, driven by product adoption, but continues to face substantial operating losses and going concern doubts.

Neuraxis, Inc. reports its 10-K filing, detailing its financial results for the fiscal year ended December 31, 2024, and outlining its business strategy focused on neuromodulation therapies, pipeline development, and regulatory compliance.

Neuraxis, Inc.'s 10-K filing provides a comprehensive overview of its share structure, regulatory environment, and business operations, highlighting its focus on neuromodulation therapies.

Director Gilad Aharon acquired 234,221 shares of Neuraxis common stock through Series B Preferred Stock dividend distributions.

Neuraxis, Inc. Chief Financial Officer, Timothy Henrichs, reported the acquisition of 7,593 shares of common stock on April 1, 2026.

Neuraxis CRO, CCO, CPO Thomas Carrico acquired 667 shares of common stock at $1.96 per share.

Neuraxis, Inc. CEO Brian Carrico acquired 8,060 shares of common stock on April 1, 2026, for $1.96 per share.

Neuraxis, Inc. Chief Medical Officer and SVP of Science & Technology, Adrian Miranda, was granted 47,569 restricted stock units as compensation.

Neuraxis Director Bradley Mitchell Watkins acquired 21,598 shares of common stock as compensation for his services.

NeurAxis, Inc. has issued its 2026 proxy statement detailing proposals for director elections, auditor ratification, and significant equity plan amendments.

Neuraxis, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) pursuant to Section 14(a) of the Securities Exchange Act of 1934.

Neuraxis, Inc. announces its 2025 Annual Meeting of Stockholders to be held on May 29, 2025, to elect directors, ratify the appointment of the accounting firm, and approve the issuance of common stock upon conversion of preferred stock.

Neuraxis, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Neuraxis, Inc. is holding its annual meeting on August 15, 2024, seeking stockholder approval on several key proposals, including director elections, auditor ratification, and amendments to the company's incentive plan and certificate of incorporation.

Bigger Capital Fund LP and associated entities have filed a Schedule 13G reporting a 6.64% beneficial ownership stake in Neuraxis, Inc.

Michael Bigger and affiliated entities have increased their beneficial ownership in Neuraxis, INC to 9.17% of outstanding common stock.

Bigger Capital Fund L.P. and District 2 Capital Fund L.P., along with Michael Bigger, have disclosed their beneficial ownership in Neuraxis, Inc., totaling 8.60% of common stock.

Investment entities led by Michael Bigger have disclosed significant passive stakes in Neuraxis, INC, collectively owning 6.99% of the common stock.

Brian P. Hannasch has reported a beneficial ownership of 1,144,374 shares, representing 12.0% of Neuraxis, Inc.'s common stock, as detailed in a recent Schedule 13G Amendment.

Brian P. Hannasch has filed an amended Schedule 13G, reporting a 7.5% beneficial ownership stake in Neuraxis, Inc., primarily for passive investment purposes.